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Wilder-Smith	A,	Leong	WY			Travelers	with	sickle	cell	disease	(SCD)	face	considerable	medical	risks	when	traveling	to	developing	tropical	countries,	including	malaria,	bacterial	infections,	hypovolemia,	and	sickle	cell-associated	vaso-occlusive	crises.1		With	increasing	number	of	international	travelers2,	increasing	number	of	travelers	with	SCD	will	travel	to	destinations	where	dengue	is	frequent.3	Immunopathological	features	of	SCD	patients	may	increase	the	risk	of	severe	dengue.	Activated	monocytes	in	SCD	might	activate	endothelial	cells	(EC)	through	different	cytokines	that	contribute	to	SCD	associated	microvascular	occlusions,	altering	EC	apoptosis,	immune	responses	and	hemopoiesis.4				We	therefore	did	a	scoping	review	to	address	the	question	whether	sickle	cell	is	associated	with	severe	dengue.	The	PubMed	search	included	the	terms	“dengue”	or	“severe	dengue”	or	“dengue	haemorrhagic	fever”	AND	“sickle	cell”.		We	had	20	hits.	Of	these	20	articles,	only	7	articles	were	deemed	to	be	relevant	with	actual	cases	reported,	and	the	full	text	was	accessed.	Table	1	summarizes	the	findings.			All	case	reports	document	a	fatal	outcome	of	a	dengue	infection	in	patients	with	sickle	cell	disease.		However,	from	case	reports	the	incidence	or	relative	risk	cannot	be	inferred,	as	case	reports	tend	to	be	biased	towards	reporting	more	severe	outcomes.	However,	the	Cuban	experience	highlighted	that	there	may	indeed	be	an	association	of	SCD	with	severe	outcomes	due	to	dengue	infections:	of	the	three	deaths	reported	during	a	dengue	outbreak	in	Havana	2001	to	2002,	2	were	in	patients	with	SCD.5		A	retrospective	analysis	of	40	patients	in	Jamaica	with	confirmed	dengue	and	SCD	in	the	years	2010-2012	showed	a	significantly	higher	case	fatality	ratio	among	SCD	patients:	12.5%	among	patients	with	either	haemoglobin	SC	disease	or	homozygous	SS	disease	when	compared	to	that	of	the	general	population	0.41%	(p	<	0.0001).	The	unadjusted	odds	of	dying	among	those	with	haemoglobin	SC	disease	compared	with	the	group	with	homozygous	SS	disease	was	OR	=	4.4	(95%	CI	0.6	to	31.7).	The	predictors	of	mortality	independent	of	sickle	cell	disease	genotype	were	a	lower	haemoglobin	concentration	at	presentation	with	an	OR	of	0.57	(95%	CI,	0.35	to	0.94).	This	is	in	contrast	to	dengue	haemorrhagic	fever	in	patients	without	SCD	where	an	increasing	haematocrit	heralds	severe	dengue..Adjusting	for	haemoglobin	concentration	at	presentation	increased	the	risk	of	death	for	the	SC	genotype	relative	to	SS	genotype	with	an	OR	=	13.4	(95%	CI	1.1	to	160.3).6		From	the	limited	data	available	to	date,	it	appears	that	the	risk	of	fatal	dengue	may	be	higher	among	patients	with	a	relatively	mild	genotype	(haemoglobin	SC),	although	no	firm	conclusions	can	be	drawn	on	the	incidence	and	extent	of	risk.	The	highest	frequency	of	sickle	cell	disease	is	found	in	tropical	regions,	particularly	sub-Saharan	Africa,	tribal	regions	of	India	and	the	Middle	East.	Migration	of	substantial	populations	from	these	high	prevalence	areas	to	low	prevalence	countries	such	as	Europe	has	dramatically	increased	in	recent	
decades.	For	individuals	with	SCD	traveling	to	dengue	endemic	countries,	frank	counseling	about	the	risks,	vigilant	preventative	measures,	and	contingency	planning	for	illness	while	abroad	are	necessary	aspects	of	the	pre-travel	visit.	SCD	patients	will	need	closer	monitoring	to	detect	the	onset	of	capillary	leakage	and	other	complications	of	dengue.	Haematocrit	is	more	difficult	to	interpret	in	such	patients,	and	a	normal	to	low	haematocrit	does	not	exclude	severe	dengue.			References			1.	 Willen	SM,	Thornburg	CD,	Lantos	PM.	Travelers	with	sickle	cell	disease.	J	
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